AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7011299
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide 0.3 mg
Trial: 7011299
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide 0.3 mg + ephedrine hydrochloride 25 mg
Trial: 19565729
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group (Flunarizine tablets)
Trial: 17419283
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg clarithromycin (C250 group)
Trial: 17419283
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg clarithromycin and 500 mg vitamin C (V-C250 group)
Trial: 17419283
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg clarithromycin (C500 group)
Trial: 11157010
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² every 3 weeks (arm A)
Trial: 11157010
Drug: Mitoxantrone 23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 23 mg/m² plus cyclophosphamide 600 mg/m² with filgrastim 5 µg/kg/d from days 2 to 15 every 3 weeks (arm B)
Trial: 11157010
Drug: Mitoxantrone 23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 23 mg/m² plus cyclophosphamide with filgrastim (arm B)
Trial: 11157010
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² (arm A)
Trial: 26508701
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (0.45 mg/day) with progesterone (200 mg/day for 12 days each month)
Trial: 26508701
Drug: Transdermal 17β‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17β‐estradiol (50 μg/day) with progesterone (200 mg/day for 12 days each month)
Trial: 21458845
Drug: Memantine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 20 mg/d
Trial: 9223203
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.25% bupivacaine (group C, n = 10)
Trial: 9223203
Drug: Intermittent hourly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent hourly bolus of 0.25% bupivacaine (group B, n = 10)
Trial: 8124207
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg bd)
Trial: 3303813
Drug: Low-dose prostaglandin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prostaglandin F2 alpha (PGF2 alpha, up to 6.0 micrograms/min)
Trial: 2809851
Drug: Coloured luting
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coloured luting agents
Trial: 27028190
Drug: tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin 0.2 mg plus solifenacin 5 mg (Group II)
Trial: 27028190
Drug: tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin 0.2 mg plus solifenacin 10 mg (Group III)
Trial: 27028190
Drug: tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin 0.2 mg (Group I)
Trial: 19221919
Drug: Therapist-guided web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided web-based cognitive behavioural treatment (web-CBT)
Trial: 16916668
Drug: Midazolam (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.4 mg.kg(‐1).h(‐1))
Trial: 7936339
Drug: Dopexamine infusion
RxNorm normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine infusion at a dose of 1 microgram/kg/m during aortic cross-clamping and 0.5 micrograms/kg/m from declamping to the end of surgery
Trial: 7936339
Drug: No dopexamine
RxNorm normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dopexamine infusion (Control Group I)
Trial: 29998356
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy applied on the right side
Trial: 29998356
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy applied on the left side
Trial: 22372531
Drug: Prasugrel (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (30 mg)
Trial: 21171738
Drug: Self-Motivational (SM)
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-Motivational (SM) orientation + Parent-Child Interaction Therapy (PCIT)
Trial: 18386606
Drug: Trimebutine 100
RxNorm normalized name: trimebutine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimebutine 100 mg t.i.d.
Trial: 12492804
Drug: Clonidine 4
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 4 micro g kg‐1 in apple juice 0.2 ml kg‐1
Trial: 12492804
Drug: Apple juice
RxNorm normalized name: apple juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple juice 0.2 ml kg‐1 (Control)
Trial: 2967184
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Bisoprolol 5 mg, Bisoprolol 10 mg, Atenolol 100 mg)
Trial: 27410392
Drug: Individualised nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised nutritional care by a dietitian, including prescription of wound healing supplements
Trial: 19800680
Drug: T suis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T suis ova (2500 live ova, 8 doses, 21-day interval)
Trial: 12172716
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: 50-ml mixture of 20 ml 0.5% bupivacaine hydrochloride, 10 ml 2% lidocaine hydrochloride, and 20 ml 0.9% sodium chloride; knee joint injected with 40 ml of the mixture; portal sites injected with 10 ml of the mixture.
Trial: 12172716
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: Same mixture as Group I with 250 micro g epinephrine added; knee joint injected with 40 ml of the mixture; portal sites injected with 10 ml of the mixture.
Trial: 12172716
Drug: Group III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: Same mixture as Group I with 50 micro g epinephrine added to 10 ml of the mixture for portal site injections; knee joint injected with 40 ml of the mixture.
Trial: 8578174
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of recombinant interferon-alpha-2b (3 MIU, 3/7 days)
Trial: 8578174
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of recombinant interferon-alpha-2b (1 MIU, 3/7 days)
Trial: 347229
Drug: Sustained-release procainamide
RxNorm normalized name: procainamide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release procainamide (PAD)
Trial: 27092789
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg once a day for 12 weeks
Trial: 22288493
Drug: Daily reports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily reports tapping experienced or experienced and witnessed negative events
Trial: 22288493
Drug: No daily
RxNorm normalized name: Aveeno Daily Moisturizing
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No daily reports
Trial: 11753127
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive therapies using thermal energy to ablate prostatic tissue
Trial: 9990599
Drug: High impedance
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High impedance steroid‐eluting pacing leads (Medtronic model 5534 and 5034)
Trial: 9990599
Drug: Standard steroid‐eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard steroid‐eluting pacing leads (Medtronic model 5524 and 5024)
Trial: 9990599
Drug: High impedance
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High impedance steroid‐eluting pacing leads (Medtronic model 5534)
Trial: 9990599
Drug: Standard steroid‐eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard steroid‐eluting pacing leads (Medtronic model 5524)
Trial: 9990599
Drug: High impedance
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High impedance steroid‐eluting pacing leads (Medtronic model 5034)
Trial: 9990599
Drug: Standard steroid‐eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard steroid‐eluting pacing leads (Medtronic model 5024)
Trial: 7579565
Drug: Cisplatin 20
RxNorm normalized name: CISPLATIN 200MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 20 mg/m2 in 15 min i.v. infusion followed by FA 500 mg/m2 in 1 h i.v. infusion, with 5-FU 500 mg/m2 i.v. bolus administered in the middle, repeated weekly for 4 weeks followed by a 2 week rest, for a maximum of six cycles.
Trial: 1377769
Drug: Synthetic substance
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic substance P (SP) at doses of 0.5, 1.0, or 1.5 pmol/kg‐1/min‐1 for 60 minutes
Trial: 6373161
Drug: Clomipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (25 to 150 mg)
Trial: 6373161
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 to 30 mg)
Trial: 24590257
Drug: Long-term antidepressant
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term antidepressant medication
Trial: 24590257
Drug: Continuing antipsychotic
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing antipsychotic medication
Trial: 24590257
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further antidepressant treatment
Trial: 19282169
Drug: Sunitinib 37.5mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5mg/day (morning dosing)
Trial: 19282169
Drug: Sunitinib 37.5mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5mg/day (evening dosing)
Trial: 19282169
Drug: Sunitinib 37.5mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5mg/day (both morning and evening dosing)
Trial: 15281507
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (droperidol and ondansetron with isoflurane and nitrous oxide)
Trial: 7406249
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone 2 mg/kg/day
Trial: 8598594
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (alteplase)
Trial: 17263767
Drug: Alcohol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.4 g/kg) during hypoglycaemia (2.8 mmol/l for 65 min)
Trial: 17263767
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during hypoglycaemia (2.8 mmol/l for 65 min)
Trial: 17263767
Drug: Alcohol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.4 g/kg) during euglycaemia
Trial: 28139557
Drug: Ranolazine 500
RxNorm normalized name: ranolazine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 500 mg twice daily
Trial: 15093870
Drug: Ranolazine 1500
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine 1500 mg twice daily
Trial: 15093870
Drug: Ranolazine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (all doses)
Trial: 254058
Drug: Dorsogluteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsogluteal injection with femur internally rotated (narcotic medication)
Trial: 254058
Drug: Dorsogluteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsogluteal injection with femur externally rotated (narcotic medication)
Trial: 254058
Drug: Dorsogluteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsogluteal injection with femur internally rotated (diazepam)
Trial: 254058
Drug: Dorsogluteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsogluteal injection with femur externally rotated (diazepam)
Trial: 254058
Drug: Dorsogluteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsogluteal injection (diazepam)
Trial: 25677380
Drug: Levamisole 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole 2.5 mg kg(‐1) orally once every other day
Trial: 15129980
Drug: Vaginal clotrimazole
RxNorm normalized name: clotrimazole Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal clotrimazole cream
Trial: 15129980
Drug: Test gel
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test gel product
Trial: 11556579
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of albendazole 400 mg (A1, n=34)
Trial: 11556579
Drug: 3 days
RxNorm normalized name: Transderm Scop 1mg/3 days Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days of albendazole 400 mg daily (A3, n=34)
Trial: 11556579
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of albendazole 400 mg daily (A5, n=35)
Trial: 11556579
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of albendazole 400 mg plus praziquantel 40 mg/kg (AIP1, n=34)
Trial: 11556579
Drug: 3 days
RxNorm normalized name: Transderm Scop 1mg/3 days Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days of albendazole 400 mg plus praziquantel 40 mg/kg daily (A3P3, n=36)
Trial: 9563866
Drug: TIVA using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA using propofol with alfentanil (high infusion rate)
Trial: 9563866
Drug: TIVA using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA using propofol with alfentanil (low infusion rate)
Trial: 30634206
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group (60 cases)
Trial: 24710341
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of CPAP therapy
Trial: 20707248
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) group: hyperbaric bupivacaine 15 mg plus 100 mcg of preservative-free morphine
Trial: 20707248
Drug: Single-shot ultrasound-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-shot ultrasound-guided femoral nerve block (FNB) group: ropivacaine 0.75% 25 ml
Trial: 12807337
Drug: EPs 7630
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPs 7630 (30 drops three times daily for 7 days)
Trial: 8865711
Drug: Balanced anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced anesthesia with 0.5% isoflurane, nitrous oxide, oxygen and intravenous fentanyl
Trial: 1510899
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam administered in conscious sedation doses
Trial: 6084856
Drug: Irradiation (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation (30 Gy) and bleomycin (5 mg i.m. 1/2‐1 h before each irradiation)
Trial: 6084856
Drug: Irradiation (55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation (55 Gy) and bleomycin (5 mg i.m. 1/2‐1 h before each irradiation)
Trial: 6084856
Drug: Bleomycin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin and adriamycin treatment
Trial: 26634942
Drug: Intravaginal 0.50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal 0.50% (6.5 mg) DHEA administered daily for 12 weeks
Trial: 26634942
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered daily for 12 weeks
Trial: 25283469
Drug: Composite of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite of 5 daily pain intensity ratings
Trial: 25283469
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily pain intensity rating
Trial: 18807079
Drug: Pulse transit
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse transit time (PTT) measurement before orthodontic treatment
Trial: 18807079
Drug: Pulse transit
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse transit time (PTT) measurement after orthodontic treatment
Trial: 18807079
Drug: Pre-treatment status
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment status
Trial: 12789992
Drug: 18% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18% carbamide peroxide gel (Colgate Simply White Clear Whitening Gel) applied twice daily after brushing with a nonwhitening dentifrice
Trial: 12789992
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available whitening dentifrice used twice daily for brushing
Trial: 9583844
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg ascorbic acid
Trial: 9583844
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg ascorbic acid
Trial: 7633987
Drug: Analgesic treatment
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic treatment (control)
Trial: 29136625
Drug: Fluoridated salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated salt (250 mg F-/kg salt) used in meals for the intervention group
Trial: 23233657
Drug: Thalidomide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (50 mg daily for 2 years)
Trial: 17872899
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy in ER-negative/PrPc-positive disease
Trial: 17872899
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy in ER-negative/PrPc-negative tumors
Trial: 15480326
Drug: Coseasonal sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coseasonal sublingual immunotherapy (SLIT) for 3 years
Trial: 15480326
Drug: Standard symptomatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard symptomatic therapy (control)
Trial: 9764616
Drug: Mifepristone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (400 mg orally)
Trial: 15932638
Drug: Glucose-insulin-potassium infusion
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium infusion (GIK)
Trial: 2837991
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/day b.i.d. combined with FT‐207 600 mg/day t.i.d.
Trial: 28961815
Drug: Routine antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antibiotic prescription monitoring and feedback based on health insurance claims data
Trial: 22903141
Drug: Steep Ramp
RxNorm normalized name: sheep wool preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steep Ramp Test (SRT); performed twice within 2 weeks; main outcome: Peak Work Rate (WRpeak)
Trial: 21483491
Drug: Interruption before
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interruption before re‐treatment
Trial: 21483491
Drug: Re‐treatment options
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re‐treatment options
Trial: 16765793
Drug: cyclosporine 0.05%
RxNorm normalized name: CYCLOSPORINE 0.05% (PF) EMULSION,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclosporine 0.05% ophthalmic emulsion
Trial: 11087764
Drug: IVIg (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (0.4 g/kg/d for 5 consecutive days)
Trial: 1609951
Drug: Diazepam 0.5
RxNorm normalized name: diazepam 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.5 mg/kg
Trial: 4082242
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg every 6 h (Phase B)
Trial: 4082242
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg every 6 h (Phase C)
Trial: 4082242
Drug: Theophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (5 mg/kg) (Phase A)
Trial: 30261748
Drug: VacuMed® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VacuMed® treatment thrice weekly for 6 weeks
Trial: 25732417
Drug: UDCA monotherapy
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA monotherapy